Your browser is no longer supported. Please, upgrade your browser.
Settings
VTVT vTv Therapeutics Inc. daily Stock Chart
VTVT [NASD]
vTv Therapeutics Inc.
Index- P/E- EPS (ttm)-0.53 Insider Own69.32% Shs Outstand51.67M Perf Week1.55%
Market Cap69.24M Forward P/E- EPS next Y-0.43 Insider Trans20.16% Shs Float9.44M Perf Month-4.29%
Income-11.40M PEG- EPS next Q-0.11 Inst Own1.90% Short Float15.90% Perf Quarter-22.09%
Sales10.60M P/S6.53 EPS this Y34.60% Inst Trans-59.04% Short Ratio2.92 Perf Half Y-46.40%
Book/sh-1.78 P/B- EPS next Y7.10% ROA-115.50% Target Price6.50 Perf Year12.61%
Cash/sh0.03 P/C46.16 EPS next 5Y- ROE19.40% 52W Range0.68 - 6.09 Perf YTD-49.43%
Dividend- P/FCF- EPS past 5Y13.90% ROI29.80% 52W High-78.00% Beta-3.43
Dividend %- Quick Ratio0.20 Sales past 5Y66.40% Gross Margin- 52W Low96.08% ATR0.07
Employees52 Current Ratio0.20 Sales Q/Q-28.00% Oper. Margin- RSI (14)48.35 Volatility5.65% 5.94%
OptionableNo Debt/Eq- EPS Q/Q66.40% Profit Margin- Rel Volume0.17 Prev Close1.37
ShortableNo LT Debt/Eq- EarningsAug 02 Payout- Avg Volume514.39K Price1.34
Recom2.00 SMA200.10% SMA50-3.00% SMA200-26.60% Volume85,592 Change-2.19%
May-30-19Initiated H.C. Wainwright Buy
Apr-10-18Downgrade Stifel Buy → Hold $12 → $1
Mar-08-18Initiated ROTH Capital Buy $17
Feb-08-18Initiated Northland Capital Outperform $28
Sep-26-16Initiated H.C. Wainwright Buy $13
Sep-04-15Initiated Canaccord Genuity Buy $15
Aug-24-15Initiated Stifel Buy $17
Aug-24-15Initiated Piper Jaffray Overweight $24
Aug-09-19 04:09PM  Largest Insider Trades of the Week GuruFocus.com
Aug-06-19 04:05PM  vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences GlobeNewswire
Jul-31-19 04:30PM  vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update GlobeNewswire
Jul-15-19 04:59PM  vTv Therapeutics to Present at 2019 Alzheimers Association International Conference Business Wire
Jun-28-19 01:03PM  Largest Insider Trades of the Week GuruFocus.com
Jun-27-19 04:30PM  vTv Therapeutics Initiates Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes Business Wire
Jun-06-19 08:00AM  vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes Business Wire -7.78%
May-29-19 12:00PM  Biotech entrepreneur seeks approval of 80-acre Triad R&D campus with 1,600 jobs American City Business Journals
May-17-19 05:47PM  Insiders Roundup: vTv Therapeutics, The Hershey GuruFocus.com
May-01-19 06:58PM  VTv Therapeutics: 1Q Earnings Snapshot Associated Press -8.00%
04:30PM  vTv Therapeutics Announces 2019 First Quarter Financial Results and Update Business Wire
Apr-04-19 10:49AM  Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv Zacks -5.95%
Apr-03-19 07:57AM  Get Over Bargain Hunting: Tap 5 Stocks With Rising P/E Zacks
Apr-02-19 07:30AM  FDA Events Can Send Stocks Soaring: Here's One That No One Is Talking About ACCESSWIRE
Mar-28-19 04:30PM  vTv Therapeutics to Present at the 14th International Conference on Alzheimers & Parkinsons Diseases Business Wire
Mar-19-19 12:56PM  Triad biopharmaceutical company seeks to raise $6 million American City Business Journals
Mar-18-19 09:00AM  vTv Therapeutics Announces $15 Million of Class A Common Stock Financings Business Wire -13.04%
Feb-27-19 08:30AM  vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update Business Wire
Jan-25-19 12:05AM  Watch These 4 Healthcare Stocks Set the Pace on Friday (1/25/19) ACCESSWIRE
Jan-16-19 02:00PM  vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study Business Wire +13.65%
Jan-02-19 03:03PM  10 trading lessons for 2019 that we learned from the 2018 stock market selloff Yahoo Finance +6.42%
09:25AM  Watch These Top Trending Stocks On Jan. 2, 2019 ACCESSWIRE
08:30AM  Biotech Rally Ahead of the Market ACCESSWIRE
Dec-31-18 10:50AM  4 Healthcare Stocks That Are Raising Eyebrows ACCESSWIRE +16.74%
07:30AM  Biotech Companies in the News ACCESSWIRE
Dec-28-18 09:20AM  4 Healthcare Stocks Gaining Speed on Friday (12/28/18) ACCESSWIRE +120.39%
Dec-03-18 07:30AM  Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group What Drives Growth in Today's Competitive Landscape GlobeNewswire +17.75%
Nov-19-18 04:00PM  vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-08-18 08:45PM  VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:39PM  VTv Therapeutics: 3Q Earnings Snapshot Associated Press
05:21PM  vTv Therapeutics Announces Third Quarter 2018 Results and Update Business Wire
Oct-31-18 10:32AM  VTv Therapeutics (VTVT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks +11.49%
Oct-29-18 06:30PM  vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market Business Wire
Oct-24-18 09:00AM  vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimers and Diabetes at the 11th Clinical Trials on Alzheimers Disease (CTAD) Conference Business Wire -5.96%
07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Tabula Rasa Healthcare, Interpublic Group of Companies, Travelport Worldwide, Weight Watchers International, vTv Therapeutics, and Ulta Beauty New Research Emphasizes Economic Growth GlobeNewswire
Oct-17-18 12:27PM  Stock Market News Daily Roundup October 17 Market Exclusive +28.42%
08:00AM  Today's Research Reports on Trending Tickers: vTv Therapeutics and Johnson & Johnson ACCESSWIRE
Oct-16-18 04:30PM  vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimers Disease (CTAD) Conference Business Wire
Oct-15-18 08:10AM  vTv Therapeutics Shares Soar in October, Near Term Catalysts, Analysts review and Target ACCESSWIRE -10.98%
Oct-11-18 08:34AM  vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session Zacks
Oct-10-18 10:30AM  This Weeks Biotech and Cannabis Stocks to Watch ACCESSWIRE +5.78%
08:00AM  Todays Research Reports on Stocks to Watch: Trevena and vTv Therapeutics ACCESSWIRE
Oct-04-18 10:30AM  Undervalued Stocks You Cant Afford to Miss ACCESSWIRE -21.76%
Oct-03-18 08:00AM  Todays Research Reports on Stocks to Watch: Inovio Pharmaceuticals and vTV Therapeutics ACCESSWIRE +70.00%
Aug-30-18 04:30PM  vTv Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Business Wire
Aug-22-18 02:56PM  VTV CEO on Alzheimer's drug: "We have not given up on it" American City Business Journals +8.18%
Aug-03-18 09:25AM  VTv Therapeutics (VTVT) Reports Q2 Loss, Tops Revenue Estimates Zacks
08:01AM  VTv Therapeutics: 2Q Earnings Snapshot Associated Press
07:30AM  vTv Therapeutics Announces Second Quarter 2018 Results and Update Business Wire
Jul-30-18 07:20AM  Breakfast Technical Briefing on ZIOPHARM Oncology and Three Other Additional Biotech Stocks ACCESSWIRE -6.15%
Jul-02-18 07:25AM  Initiating Free Research Reports on ZIOPHARM Oncology and Three Other Biotech Equities ACCESSWIRE -6.49%
Jun-22-18 09:00AM  vTv Therapeutics to Present a Poster at the American Diabetes Associations 78th Scientific Sessions Business Wire -5.99%
Jun-12-18 04:30PM  vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study Business Wire
08:25AM  Research Report Identifies Avangrid, Entercom Communications, Kennedy-Wilson, Emerson Electric, Amgen, and vTv Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Jun-08-18 07:30AM  [$$] Ron Perelman Bitten by Biotech Stock Deal Barrons.com
Jun-01-18 08:46AM  vTv Therapeutics (VTVT) Catches Eye: Stock Jumps 6.9% Zacks +5.62%
07:42AM  VTv Therapeutics inks licensing agreement with Chinese biotech firm American City Business Journals
May-31-18 07:33AM  vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTvs PDE4 Inhibitor in China and Other Pacific Rim Territories Business Wire +6.91%
May-30-18 07:25AM  Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks ACCESSWIRE
May-15-18 04:52PM  VTv Therapeutics: 1Q Earnings Snapshot Associated Press -8.99%
04:30PM  vTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent Highlights Business Wire
May-11-18 08:20AM  Todays Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma ACCESSWIRE -8.37%
May-09-18 04:30PM  vTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B Results in June Business Wire
Apr-30-18 06:00AM  Key executive leaving High Point biotech firm following disappointing trial results American City Business Journals -8.21%
Apr-18-18 08:20AM  Todays Research Reports on Stocks to Watch: vTv Therapeutics and InVivo Therapeutics ACCESSWIRE +84.87%
Apr-17-18 05:06PM  vTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setback American City Business Journals +43.25%
02:43PM  VTv Therapeutics shares surge 40 percent American City Business Journals
Apr-16-18 06:00AM  Cambrex, poised for another expansion, buys two properties for $10.2M American City Business Journals +9.30%
Apr-10-18 10:15AM  vTv Therapeutics Crashes on Alzheimer's Drug Study Failure Zacks -78.09%
09:36AM  Stifel Sees Challenging Road Ahead For vTv Therapeutics After Failed Alzheimer's Trial Benzinga
02:29AM  Shares of vTv Therapeutics plummet as Alzheimer's study disappoints MarketWatch
Apr-09-18 07:15PM  Vtv Therapeutics price plummets after disappointing trial results American City Business Journals
04:46PM  vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimers Disease Business Wire
Mar-27-18 07:20AM  Wired News vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 Diabetes ACCESSWIRE
Mar-26-18 07:17AM  UPDATED: vTv Therapeutics reaches milestone in study of its diabetes drug American City Business Journals
Mar-22-18 05:00PM  vTv Therapeutics Announces Completion of Phase 1b Study Evaluating TTP399 for the Treatment of Type 1 Diabetes Business Wire
03:25PM  Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant Benzinga
Feb-28-18 05:04AM  VTv Therapeutics reports 4Q loss Associated Press -8.72%
Feb-27-18 05:15PM  vTv Therapeutics Reports 2017 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights Business Wire
Feb-16-18 08:25AM  Detailed Research: Economic Perspectives on OUTFRONT Media, Mylan N.V, Axcelis Technologies, Patterson-UTI Energy, SAExploration, and vTv Therapeutics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-11-18 07:31AM  The Triad's best and worst stocks of 2017 (Slideshow) American City Business Journals
Dec-29-17 12:37PM  ETFs with exposure to vTv Therapeutics, Inc. : December 29, 2017 Capital Cube +8.09%
Dec-26-17 07:30AM  Wired News vTv Therapeutics Signs Licensing Agreement with Hangzhou Zhongmei Huadong Pharmaceutical for its GLP-1r Agonist Diabetes Program in China and Other Pacific Rim Territories ACCESSWIRE
Dec-22-17 12:56PM  Another day, another deal: vTv Therapeutics signs licensing agreement with Reneo American City Business Journals -6.32%
Dec-21-17 04:30PM  vTv Therapeutics and Reneo Pharmaceuticals Enter Licensing Agreement for PPAR-Delta Program Business Wire
03:00AM  vTv Therapeutics Announces Licensing Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co. to Rights for vTvs GLP-1r Agonist Diabetes Program in China and Other Pacific Rim Territories Business Wire
Dec-20-17 04:14PM  vTv Therapeutics raises $10 million American City Business Journals
Dec-04-17 07:55AM  Market Trends Toward New Normal in Patterson-UTI Energy, SAExploration, vTv Therapeutics, Outfront Media, Mylan N.V, and Axcelis Technologies Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-13-17 07:30AM  vTv to Host Key Opinion Leader Event to Discuss the Current State of Clinical Development in Alzheimers Disease Business Wire
Nov-08-17 04:35PM  vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes Business Wire
Nov-06-17 12:42PM  ETFs with exposure to vTv Therapeutics, Inc. : November 6, 2017 Capital Cube
Nov-03-17 10:05AM  vTv Therapeutics, Inc. :VTVT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
Nov-02-17 08:30AM  Report: Developing Opportunities within Echelon, NII Holdings, ANI Pharmaceuticals, Zion Oil & Gas, vTv Therapeutics, and Sears Holdings Future Expectations, Projections Moving into 2018 GlobeNewswire
05:50AM  VTv Therapeutics reports 3Q loss Associated Press
Nov-01-17 04:30PM  vTv Therapeutics Reports Third Quarter 2017 Financial and Operational Results Business Wire
Oct-30-17 07:00AM  vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimers Disease (CTAD) Business Wire
Oct-12-17 08:52AM  Why vTv Therapeutics (VTVT) Could Be Positioned for a Surge Zacks
Oct-11-17 12:11PM  ETFs with exposure to vTv Therapeutics, Inc. : October 11, 2017 Capital Cube +6.06%
Sep-07-17 07:00AM  vTv Therapeutics Presents Further Dose Response Analysis from Phase 2 Study of its GLP-1 Receptor Agonist at 53rd Annual Meeting of the European Association for the Study of Diabetes Business Wire
Sep-06-17 02:56PM  vTv Therapeutics snags funding for study of its diabetes-targeting drug American City Business Journals +6.78%
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase IIb clinical trials to treat type 2 diabetes, as well as is in Phase II clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing a portfolio of investigational drug candidates, such as HPP737 and HPP971 to treat inflammatory disorders. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERELMAN RONALD O10% OwnerAug 22Buy1.3850,00069,00021,688,714Aug 22 06:37 PM
PERELMAN RONALD O10% OwnerAug 19Buy1.31150,000195,90021,638,714Aug 19 07:38 PM
PERELMAN RONALD O10% OwnerAug 06Buy1.651,212,1212,000,00021,488,714Aug 06 04:40 PM
PERELMAN RONALD O10% OwnerJul 09Buy1.651,212,1212,000,00020,276,593Jul 09 04:35 PM
PERELMAN RONALD O10% OwnerJun 25Buy1.651,212,1212,000,00019,064,472Jun 26 08:52 AM
PERELMAN RONALD O10% OwnerMay 15Buy1.841,358,6982,500,00417,852,351May 16 07:54 AM
KINDLER JEFFREY BExecutive ChairmanMar 10Option Exercise0.0011,666023,333Mar 11 04:06 PM
PERELMAN RONALD O10% OwnerFeb 28Buy1.84815,2171,499,99916,493,653Feb 28 04:11 PM
PERELMAN RONALD O10% OwnerFeb 14Buy1.84815,2171,499,99915,678,436Feb 15 09:27 AM
PERELMAN RONALD O10% OwnerJan 29Buy1.84815,2171,499,99914,863,219Jan 30 04:31 PM
PERELMAN RONALD O10% OwnerJan 16Buy1.84815,2171,499,99914,048,002Jan 18 04:35 PM
PERELMAN RONALD O10% OwnerDec 27Buy1.84815,2171,499,99913,232,785Dec 27 08:00 PM
PERELMAN RONALD O10% OwnerNov 29Buy1.331,879,7002,500,00112,417,568Nov 30 04:30 PM
PERELMAN RONALD O10% OwnerNov 06Buy1.331,879,6992,500,00010,537,868Nov 07 06:55 AM
PERELMAN RONALD O10% OwnerSep 27Buy1.331,879,6992,500,0008,658,169Oct 01 06:37 PM
SAVAS PAUL GDirectorSep 06Buy1.005,0005,00091,781Sep 06 06:51 PM
PERELMAN RONALD O10% OwnerSep 06Buy1.331,879,6992,500,0006,778,470Sep 10 05:46 PM